Home » Stocks » AEterna Zentaris

AEterna Zentaris Inc. (AEZS)

Stock Price: $0.357 USD 0.007 (2.03%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $0.360 +0.003 (0.81%) Oct 23, 7:53 PM

Stock Price Chart

Key Info

Market Cap 22.38M
Revenue (ttm) 532,000
Net Income (ttm) -6.04M
Shares Out 62.68M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.357
Previous Close $0.350
Change ($) 0.007
Change (%) 2.03%
Day's Open 0.354
Day's Range 0.345 - 0.363
Day's Volume 520,074
52-Week Range 0.325 - 1.540

More Stats

Market Cap 22.38M
Enterprise Value 15.08M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 62.68M
Float 58.74M
EPS (basic) -0.35
EPS (diluted) -0.21
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.57M
Short Ratio 0.56
Short % of Float 2.68%
Beta 2.16
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 42.07
PB Ratio 24.04
Revenue 532,000
Operating Income -10.24M
Net Income -6.04M
Free Cash Flow -10.73M
Net Cash 7.30M
Net Cash / Share 0.12
Gross Margin 8.36%
Operating Margin -1,925.19%
Profit Margin -1,135.70%
FCF Margin -2,015.98%
ROA -23.27%
ROE -389.57%
ROIC 256.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.50*
Low
4.50
Current: $0.357
High
4.50
Target: 4.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.5326.880.920.910.550.016.182.054.7127.70
Revenue Growth-98.02%2812.35%1.32%67.16%4854.55%-99.82%200.78%-56.37%-83.02%-
Gross Profit0.1224.780.920.910.550.016.121.464.499.00
Operating Income-10.249.84-23.07-29.48-34.88-37.40-27.48-29.74-31.71-24.81
Net Income-6.044.19-16.80-24.96-50.14-16.566.82-20.41-27.07-28.45
Shares Outstanding17.4916.4414.9610.352.760.590.290.200.160.13
Earnings Per Share-0.350.24-1.12-2.41-18.14-28.0623.12-103.00-172.00-226.00
Operating Cash Flow-10.736.83-22.91-29.01-33.84-31.08-19.98-30.82-26.24-31.71
Capital Expenditures-0.020.16-0.060.48-0.06-0.09-0.27-0.71-0.05
Free Cash Flow-10.736.84-22.76-29.07-33.37-31.14-20.07-31.09-26.95-31.76
Cash & Equivalents8.2014.938.1622.5041.7135.6944.0740.3547.6934.76
Total Debt0.90-------0.060.06
Net Cash / Debt7.3014.938.1622.5041.7135.6944.0740.3547.6334.70
Assets19.9825.0122.2031.6651.5047.4459.2067.6775.3761.45
Liabilities22.4423.1024.9825.4529.8832.9542.1374.3679.9279.02
Book Value-2.461.91-2.786.2121.6214.4817.06-6.70-4.55-17.58
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AEterna Zentaris Inc.
Country United States
CEO Klaus Wolfgang Paulini

Stock Information

Ticker Symbol AEZS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AEZS
IPO Date July 18, 1996

Description

Aeterna Zentaris, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.